Top

Published in:

01-03-2013 | Review Article

The role of immunity and inflammation in the development of diabetic complications

Authors: Maria F. Lopes-Virella, Gabriel Virella

Published in: Diabetology International | Issue 1/2013

Abstract

Our group has carried out pivotal clinical studies on large cohorts of type 1 and type 2 diabetes to determine the impact of modified LDL-IC as well as inflammatory cytokines/adipokines and acute-phase reactant proteins in the development of diabetic complications. We have demonstrated that high levels of specific LDL modifications in circulating ICs correlate with increased risk for the development and progression of macrovascular disease, nephropathy, and retinopathy, frequently exceeding conventional risk factors in their predictive power. In cardiovascular disease, differences in the type of LDL modification and the stage of disease seem to lead to/predict different outcomes. The differences observed with ICs containing different types of modified LDL raises interesting questions about the role of the predominant LDL modification in the ICs and the cellular patterns of macrophage activation, survival, and apoptosis that result from LDL-IC ingestion. The differences observed in the predictive power of modified LDL-ICs at different stages of CVD development strongly suggest that modified LDL-ICs are causally related with the development of atherosclerosis and/or plaque instability. The association of cytokines/adipokines and acute-phase reactant proteins with the development of complications in type 1 diabetes is less strong than that observed with modified LDL-ICs and occurs at a later phase of the development of complications. In conclusion, the human humoral autoimmune response to modified forms of LDL is a typical adaptive response, with a switch to IgG synthesis and increasing antibody affinity that leads to the release of proinflammatory mediators, and it has unquestionable pathogenic characteristics.

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.PubMedCrossRef

Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem. 2010;51:229–51.PubMedCrossRef

Holvoet P. Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease. Ther Apher. 1999;3:287–93.PubMedCrossRef

Lopes-Virella MF, Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci. 2003;8:s750–68.PubMedCrossRef

Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 1994;108:S21–9.PubMedCrossRef

Henriksen T, Mahoney ME, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis. 1983;3:149–58.PubMedCrossRef

Arai K, Kita T, Yokode M, Narumiya S, Kawai C. Multiple receptors for modified LDL in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized LDL. Biochem Biophys Res Commun. 1989;159:1375–9.PubMedCrossRef

Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized LDL. J Biol Chem. 1993;268:11811–8.PubMed

Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem. 1989;264:2599–604.PubMed

10.

Hoff HF, O’Neil J, Chisolm GM, Cole TB, Quehenberger O, Esterbauer H, Jurgens G. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis. 1989;9:538–49.PubMedCrossRef

11.

Fogelman AM, Schechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesterol ester accumulation in human monocytes/macrophages. Proc Natl Acad Sci USA. 1980;77:2214–8.PubMedCrossRef

12.

Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 1983;3:215–22.PubMedCrossRef

13.

Henriksen T, Evensen SA, Carlander B. Injury to human endothelial cells in culture induced by LDL. Scand J Clin Lab Investig. 1979;39:361–4.CrossRef

14.

Rajavashisth TB, Andalibi A, Territo MC. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified LDL. Nature. 1990;344:254–7.PubMedCrossRef

15.

Kugiyama K, Sakamoto T, Musumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferrable lipids in oxidized LDL stimulate PAI-1 and inhibit tPA release from endothelial cells. Circ Res. 1993;73:335–43.PubMedCrossRef

16.

Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA. 1987;84:2995–8.PubMedCrossRef

17.

Berliner JA, Territo MC, Sevanian A, Raimin S, Kim JA, Bamshad B, Ester-son M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Investig. 1990;85:1260–6.PubMedCrossRef

18.

Kume N, Cybulsky MI, Gimbrone MAJ. Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Investig. 1992;90:1138–44.PubMedCrossRef

19.

Kahn BV, Parthasarathy SS, Alexander RW, Medford RM. Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Investig. 1995;95:1262–70.CrossRef

20.

Takei A, Huang Y, Lopes-Virella MF. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis. 2001;154:79–86.PubMedCrossRef

21.

Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 2002;99:15596–601.PubMedCrossRef

22.

Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep. 2002;4:228–37.PubMedCrossRef

23.

Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Investig. 1994;70:138–51.PubMed

24.

Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Investig. 1995;96:1395–403.PubMedCrossRef

25.

De Boer OJ, van der Wal AC, Verhagen CE, Becker AE. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol. 1999;188:174–9.PubMedCrossRef

26.

Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827–35.PubMedCrossRef

27.

Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984;25:1109–16.PubMed

28.

Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262:3603–8.PubMed

29.

Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325–35.PubMedCrossRef

30.

Yla-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32–40.PubMedCrossRef

31.

Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996;16:222–9.PubMedCrossRef

32.

Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000;95:135–44.PubMedCrossRef

33.

Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007;190:359–69.PubMedCrossRef

34.

Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010;134:55–65.PubMedCrossRef

35.

Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G. The levels of oxidized LDL and AGE-LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011;60:582–9.PubMedCrossRef

36.

Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006;47:1975–83.PubMedCrossRef

37.

Virella G, Atchley DH, Koskinen S, Zheng D, Lopes-Virella M. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002;105:81–92.PubMedCrossRef

38.

Virella G, Carter RE, Saad A, Crosswell EG, Game BA, Lopes-Virella MF. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008;127:394–400.PubMedCrossRef

39.

Atchley DH, Lopes-Virella MF, Zheng D, Virella G. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002;45:1562–71.PubMedCrossRef

40.

Virella G, Thorpe S, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004;45:1859–67.PubMedCrossRef

41.

Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005;12:68–75.PubMed

42.

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012;35:1333–40.PubMedCrossRef

43.

Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012;27:1416–23.PubMedCrossRef

44.

Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011;214:462–7.PubMedCrossRef

45.

Lopes-Virella MF, Baker NL, Hunt KJ, Moritz T, Virella G, VADT Investigators. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012;224:526–31.PubMedCrossRef

46.

Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Investig. 1995;95:2611–9.PubMedCrossRef

47.

Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–94.PubMedCrossRef

48.

Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–8.PubMedCrossRef

49.

Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis. 2002;44:357–68.PubMedCrossRef

50.

Jarrett RJ. Atherosclerosis, diabetes and obesity. Proc Nutr Soc. 1981;40:209–12.PubMedCrossRef

51.

Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180–4.PubMedCrossRef

52.

Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Investig. 1994;94:2493–503.PubMedCrossRef

53.

Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009;50(Suppl):S382–7.PubMedCrossRef

54.

Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991;11:1356–67.PubMedCrossRef

55.

Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997;135:161–70.PubMedCrossRef

56.

Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikainen MO. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol. 2006;26:576–83.PubMedCrossRef

57.

de Boer OJ, van der Wal AC, Houtkamp MA, Ossewaarde JM, Teeling P, Becker AE. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res. 2000;48:402–8.PubMedCrossRef

58.

Lim WS, Timmins JM, Seimon TA, Sadler A, Kolodgie FD, Virmani R, Tabas I. Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation. 2008;117:940–51.PubMedCrossRef

59.

Hundal RS, Gomez-Munoz A, Kong JY, Salh BS, Marotta A, Duronio V, Steinbrecher UP. Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels. J Biol Chem. 2003;278:24399–408.PubMedCrossRef

60.

Tohyama Y, Yamamura H. Protein tyrosine kinase, syk: a key player in phagocytic cells. J Biochem. 2009;145:267–73.PubMedCrossRef

61.

Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med. 1997;186:1027–39.PubMedCrossRef

62.

Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol. 1999;19:1600–7.PubMedCrossRef

63.

Luo Y, Pollard JW, Casadevall A. Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. J Biol Chem. 2010;285:4232–42.PubMedCrossRef

64.

Chen JH, Riazy M, Wang SW, Dai JM, Duronio V, Steinbrecher UP. Sphingosine kinase regulates oxidized low density lipoprotein-mediated calcium oscillations and macrophage survival. J Lipid Res. 2010;51:991–8.PubMedCrossRef

65.

Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.PubMedCrossRef

66.

Lebman DA, Spiegel S. Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling. J Lipid Res. 2008;49:1388–94.PubMedCrossRef

67.

Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010;5(9):e12534. doi:10.1371/journal.pone.0012534.

68.

Smith KJ, Twal WO, Soodavar F, Virella G, Lopes-Virella MF, Hammad SM. Heat shock protein 70B′ (HSP70B′) expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010;285:15985–93.PubMedCrossRef

69.

Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-Virella MF. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009;202:394–404.PubMedCrossRef

70.

Viita H, Narvanen O, Yla-Herttuala S. Different apolipoprotein B breakdown patterns in models of oxidized low density lipoprotein. Life Sci. 1999;65:783–93.PubMedCrossRef

71.

Hoff HF, Zyromski N, Armstrong D, O’Neil J. Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages. J Lipid Res. 1993;34:1919–29.PubMed

72.

Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15–26.PubMedCrossRef

73.

Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011;2:27–38.PubMedCrossRef

74.

Loftus IM, Naylor AR, Bell PR, Thompson MM. Plasma MMP-9—a marker of carotid plaque instability. Eur J Vasc Endovasc Surg. 2001;21:17–21.PubMedCrossRef

75.

Pelisek J, Rudelius M, Zepper P, Poppert H, Reeps C, Schuster T, Eckstein HH. Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc Dis. 2009;28:601–10.PubMedCrossRef

76.

Hoke M, Schillinger M, Zorn G, Wonnerth A, Amighi J, Mlekusch W, Speidl W, Maurer G, Koppensteiner R, Minar E, Wojta J, Niessner A. The prognostic impact of soluble apoptosis-stimulating fragment on mortality in patients with carotid atherosclerosis. Stroke. 2011;42:2465–70.PubMedCrossRef

77.

Blanco-Colio LM, Martin-Ventura JL, Tunon J, Garcia-Camarero T, Berrazueta JR, Egido J. Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function? Atherosclerosis. 2008;201:407–12.PubMedCrossRef

Title: The role of immunity and inflammation in the development of diabetic complications
Authors: Maria F. Lopes-Virella
Gabriel Virella
Publication date: 01-03-2013
Publisher: Springer Japan
Published in: Diabetology International / Issue 1/2013
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-013-0105-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Cold-loaded pain sensation test and current perception threshold for evaluating diabetic neuropathy

Baseline predictive factors for glycemic control in Japanese type 2 diabetes patients treated with insulin glargine plus oral antidiabetic drugs: ALOHA study subanalysis

A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide

Analysis of clinical factors contributing to the postglucagon increment in C-peptide levels in Japanese patients with type 2 diabetes: comparison with basal C-peptide levels and 24-h urinary C-peptide excretion

Outcomes of 6 years of activities by the Tokushima Medical Association’s Steering Committee for Diabetes Prevention to prevent type 2 diabetes in the general population of Tokushima Prefecture

A patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitol

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials